Tetraphase Selects SHYFT to Support Data and Analytics for Launch

Published on: 

Pharmaceutical Executive

SHYFT Analytics, recently acquired by Medidata Solutions to create its Intelligent Platform for Life Sciences, announced Tetraphase Pharmaceuticals has selected its platform to support the commercial launch of eravacycline, its antibiotic candidate developed to address multidrug-resistant bacteria.

Eravacycline is currently being developed for the treatment of complicated intra-abdominal infections (cIAI). Pending a decision by the U.S. Food and Drug Administration, Tetraphase plans to launch the broad-spectrum antibiotic in the U.S. later in 2018.